JP2009510134A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510134A5
JP2009510134A5 JP2008533837A JP2008533837A JP2009510134A5 JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5 JP 2008533837 A JP2008533837 A JP 2008533837A JP 2008533837 A JP2008533837 A JP 2008533837A JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5
Authority
JP
Japan
Prior art keywords
gastrin
pharmaceutical composition
seq
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008533837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001644 external-priority patent/WO2007041833A1/en
Publication of JP2009510134A publication Critical patent/JP2009510134A/ja
Publication of JP2009510134A5 publication Critical patent/JP2009510134A5/ja
Withdrawn legal-status Critical Current

Links

JP2008533837A 2005-10-07 2006-10-06 Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用 Withdrawn JP2009510134A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72491905P 2005-10-07 2005-10-07
PCT/CA2006/001644 WO2007041833A1 (en) 2005-10-07 2006-10-06 Combined use of dpp iv inhibitors and gastrin compounds

Publications (2)

Publication Number Publication Date
JP2009510134A JP2009510134A (ja) 2009-03-12
JP2009510134A5 true JP2009510134A5 (https=) 2009-09-24

Family

ID=37942251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533837A Withdrawn JP2009510134A (ja) 2005-10-07 2006-10-06 Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用

Country Status (8)

Country Link
US (2) US20090054314A1 (https=)
EP (1) EP1951286A4 (https=)
JP (1) JP2009510134A (https=)
CN (1) CN101365476A (https=)
AU (1) AU2006301892A1 (https=)
BR (1) BRPI0616949A2 (https=)
CA (1) CA2625150A1 (https=)
WO (1) WO2007041833A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
DE60329724D1 (de) 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20110020797A1 (en) * 2007-02-09 2011-01-27 Bristol-Myers Squibb Company Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors
EP2190533A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
WO2009033730A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratoires Ag Peptide gxgrgdspca as a therapeutic agent
WO2010079433A2 (en) * 2009-01-07 2010-07-15 Glenmark Pharmaceuticals, S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor
US8808689B1 (en) * 2012-09-27 2014-08-19 Perle Bioscience, Inc. Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
HUE070649T2 (hu) 2017-10-19 2025-06-28 Teijin Pharma Ltd Benzimidazol-származékok és felhasználásuk
MA54619A (fr) * 2018-12-28 2021-11-03 Mitsubishi Tanabe Pharma Corp Cristal de composé d'acide pyrophosphorique
EP4376866A4 (en) * 2021-06-10 2025-10-08 Fouad Kandeel COMPOSITIONS AND METHODS FOR ISLET OF LANGERHANS TRANSPLANTS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1743655B1 (en) * 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
KR20080067009A (ko) * 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
CN1486204A (zh) * 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
CA2442177A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
AU2003283004A1 (en) * 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
WO2005072045A2 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels

Similar Documents

Publication Publication Date Title
JP2013155195A5 (https=)
JP2009538348A5 (https=)
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
JP2009510134A5 (https=)
EP2368900A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
TW200400199A (en) Hepatitis C inhibitor tri-peptides
WO2008021733A3 (en) Tetrazolyl acyclic hepatitis c serine protease inhibitors
EP1673385A1 (en) Macrocyclic peptides active against the hepatitis c virus
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
JP2013503862A5 (https=)
WO2011080102A3 (en) Glp-1 analogues and derivatives
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
JP2010505831A5 (https=)
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
JP2010536714A5 (https=)
WO2008069917A3 (en) Novel cyclic peptides
JP2006514104A5 (https=)
JP2006506942A5 (https=)
JP2010513327A5 (https=)